Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013

Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYS: PFE) today announced that Wyeth LLC, its wholly-owned subsidiary, has notified The Bank of New York Mellon, as trustee under the applicable indenture, of its election to fully redeem all of its outstanding 5.500% Notes due March 15, 2013 (after giving effect to a December 4, 2003 upward interest rate adjustment of 0.25%) (CUSIP No. 983024AA8) (the "Notes"). The aggregate principal amount of Notes currently outstanding is $1.5 billion. The redemption date for the Notes will be December 26, 2012 (the "Redemption Date").

The redemption price ("Redemption Price") for the Notes will be a price equal to the greater of (i) 100% of the principal amount of the Notes, or (ii) the sum, as determined by the Quotation Agent (as defined in the Global Note, the form of which was filed with the Securities and Exchange Commission as part of Exhibit 4.4 to Wyeth's Annual Report on Form 10-K for the fiscal year ended December 31, 2002 (File No. 001-01225) (the "Global Note")), of the present value of the principal amount of the Notes and the remaining scheduled payments of interest on the Notes from the Redemption Date to the maturity date of the Notes, exclusive of interest accrued to the Redemption Date, discounted from their respective scheduled payment dates to the Redemption Date on a semiannual basis (assuming a 360-day year of twelve 30-day months) at the Treasury Rate (as defined in the Global Note) plus 25 basis points, in each case plus accrued and unpaid interest on the principal amount being redeemed to (but excluding) the Redemption Date.

On and after the Redemption Date, the Redemption Price will become due and payable in respect of the Notes, and interest on the Notes will cease to accrue on and after such date.

Notice of the redemption of the Notes (the "Notice of Redemption") is expected to be mailed on November 26, 2012. The redemption will be effected in accordance with the applicable terms of the indenture under which the Notes were issued.

The paying agent for the redemption is The Bank of New York Mellon. The relevant contact information for The Bank of New York Mellon is set forth in the Notice of Redemption.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of the Notes and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Media:
Pfizer
Joan Campion, 212-733-2798
or
Investors:
Pfizer
Suzanne Harnett, 212-733-8009

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS:

The article Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.